Concurrent Neoadjuvant Chemo/Endocrine Therapy in HER2+ Breast Cancer

The usual approach to care for hormone receptor positive, HER2 positive breast cancer is chemotherapy and HER2 targeted therapy followed by endocrine therapy and surgery. The purpose of this Research Study is to see if taking endocrine therapy with the chemotherapy and HER2 directed therapy increases patients response to therapy at the time of surgery

NCT Number	NCT07506876
Lead Sponsor	Legacy Health System
Conditions	Breast Cancer - Infiltrating Ductal Carcinoma, HER-2 Positive Breast Cancer
Enrollment	30 participants
Start Date	2026-04-27
Primary Completion	2027-12 (estimated)
Study Completion	2027-12 (estimated)
Updated on ClinicalTrials.gov	2026-05-01